Stratagen Quantitative Prostate MRI Platform Pilot Study
Interventional
Phase not listed
Virginia Urology
Last Updated: March 6, 2026 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions.
* What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters?
Participants will:
- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
Treatment Category
Device
Required Mutations
None
Trial Started
September 24, 2025
Last Updated by Sponsor
March 6, 2026
Estimated Completion
March 31, 2026
Contact Study
Eligibility
Inclusion Criteria
* Subject has a prostate that would be considered for biopsy
* Age 40-90 years
* PSA ≥ 2.5
* Subject has been informed of the nature of the study and has provided written informed consent
Exclusion Criteria
* Contraindication for MRI
* Prostate biopsy within the previous 12 weeks
* Implant in the pelvis that may cause artifact on MRI (e.g. hip replacement)
* History of prostatectomy or other local prostate cancer therapy (e.g., cryotherapy or brachytherapy), or previous pelvic irradiation
* Currently enrolled in another investigational drug or device study that clinically interferes with this study
* Unable to comply with the study requirements or follow up schedule
* Any condition the Investigator believes would interfere with the intent of this study or would make participation not in the best interest of the subject
Do you think this trial is incorrectly appearing?
Design Details
AllocationN/A
Intervention ModelSingle Group Assignment
MaskingNone (Open Label)
Number to Enroll75
Arms & Interventions
Arms
Interventions
Type: Experimental
Description:
Interventions:
MRI
Outcome Measures
Primary Outcome Measures
Safety: no SAEs attributable to the Stratagen Quantitative Prostate MRI Platform, as determined by participating Investigator according to CTCAE guidelinesBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)
All serious adverse events attributable to the Stratagen Quantitative Prostate MRI Platform will be reported.
• Feasibility: collection of the data necessary to produce measurable quantitative T1 and T2 relaxation times (milliseconds) maps (images) for at least 80% of pixels fully contained within the prostate for at least 80% of subjectsBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)